Background: BCRP acts as a xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP-dependent increase in the efflux of rhodamine 123.
Positive Control: Highly expressed in placenta.
Immunogen: Synthetic peptide derived from human BCRP protein.
Purification Method: Antigen Immunoaffinity Purification.
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide.
References: 1. Zhou, W., et al. 'The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.' Nat. Med. 2001, 7, 1028-1034.
2. Itoda, M., et al. ''Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.' Drug Metab. Pharmacokinet. 2003, 18, 212-217.
3. Zamber, C.P., et al. 'Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.' Pharmacogenetics 2003, 13, 19-28.
UniProt: Q9UNQ0.
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
